摘要
Abstract
Objective To explore the clinical efficacy of Bevacizumab and Capecitabine combined with Oxaliplatin in the treatment of elderly patients with advanced gastric cancer, as well as its effect on serum tumor markers and quality of life. Methods From February 2014 to August 2016, 60 patients diagnosed with advanced gastric cancer were treated with laparoscopic radical gastrectomy. The patients were randomly divided into the control group and the treatment group, 30 cases in each group. The control group was treated with Doc-etaxel 75 mg/m2 and Cisplatin 75 mg/m2 on the first day after operation, and intravenous infusion of Fluorouracil 75 mg/ (m2·d) on 1-5 d for 25 h, once every 3 weeks;the treatment group was given intravenous infusion of Oxaliplatin injection 120 mg/m2 on the first day after operation, and 1-14 d intravenous infusion of Bevacizumab 7. 5 mg/m2, Capecitabine Tablets 2000 mg/m2 twice a day. The changes of serum tumor markers were measured before and after treatment, and the progression time and mean survival time of the two groups were recorded. The clinical quality and the adverse reactions were compared between the two groups by using the hospi-tal′s homemade questionnaires. Results After treatment, the levels of CA199, CA242 and CEA in the treatment group were ( 194. 2 ± 45. 8 ) mg/L, ( 32. 9 ± 8. 1 ) mg/L and ( 18. 1 ± 6. 2 ) mg/L, respectively, which were significantly lower than ( 279. 6 ± 46. 9 ) mg/L, ( 58. 7 ± 8. 8 ) mg/L, ( 29. 7 ± 7. 4 ) mg/L in the control group, the serum tumor markers in the two groups were significantly lower than before treatment ( t=7. 13, 11. 81, 6. 58, P=0. 00, 0. 00, 0. 00 );The progression time and mean survival time of the treatment group were ( 6. 2 ± 3. 1 ) months and ( 11. 8 ± 4. 2 ) months, which were significantly longer than ( 4. 1 ± 2. 0 ) months and ( 7. 9 ± 1. 9 ) months in the control group ( t=3. 11, 4. 63, P=0. 00, 0. 00 ) . After treatment, the physical symptoms, sleep quality, mental state and social emotion scores of the treatment group were significantly higher than those of the control group. The total effective rate in the treatment group was 76. 67%, which was significantly higher than 43. 33% in the control group (χ2 = 6. 94, P=0. 00 ) . Conclusion Bevacizumab and Capecitabine combined with Oxaliplatin in the treatment of elderly patients with advanced gastric cancer have significant efficacy and less adverse reactions, which is beneficial to improve the quality of life of patients and prolong their survival.关键词
晚期胃癌/贝伐单抗/卡培他滨/奥沙利铂/肿瘤标志物/生活质量Key words
advanced gastric cancer/Bevacizumab/Capecitabine/Oxaliplatin/tumor markers/quality of life分类
医药卫生
